Networks of Centres of Excellence of Canada
Government of Canada

Common menu bar links

Centre for Commercialization of Regenerative Medicine - CCRM

$30 million for 2011-23
About   |   News   |   Features   |   Videos
Centre for Commercialization of Regenerative Medicine

Headquarters
Toronto, Ontario

President and CEO
Michael May Michael May

Chief Scientific Officer
Peter Zandstra Peter Zandstra

Board chair
Michael Nobrega Michael Nobrega

Turning the promise of regenerative medicine into reality


The opportunity

Regenerative medicine (RM)-based therapies hold enormous potential to repair, regenerate or replace diseased cells, tissues and organs. But many of these potentially life-changing treatments never reach patients because they are not successfully moved from the lab to the clinic. Fortunately, Canada is a global hotbed for stem cell research and bioengineering, and a leader in cell manufacturing. The Centre for Commercialization of Regenerative Medicine (CCRM) was founded to bridge the gap between academia and industry, and enable promising technologies to reach the market. Its mission has evolved to be the preferred global destination for the best people, technologies, clinical trials, companies and investments in RM, and a premier global enabler of clinically-tested revolutionary new medical therapies and foundational technologies in RM.

How CCRM is seizing the opportunity

CCRM overcomes two major bottlenecks in RM commercialization: a dearth of early stage capital and access to centralized research infrastructure. CCRM provides small- and medium-sized enterprises, large multinationals and emerging biotechnology companies with a single entry point for accessing Canada-wide RM expertise and infrastructure. CCRM’s industry network includes around 100 Canadian and international RM companies that can access a fully-resourced, 40,000 ft˛ (~4,000 m˛) facility in the MaRS Centre in Toronto that houses a large, fully-equipped containment level 2 (CL2) laboratory, and a stand-alone 14,000 ft˛ (~1,300 m˛) good manufacturing practices (GMP) facility, to be operational in 2018.

CCRM is capitalizing on its extensive pipeline of intellectual property to bundle promising technologies into 10 new companies that are strategic and leverage expertise, funding and excellent science.

Among the results

  • CCRM works closely with other CECRs and federally-funded Networks on knowledge translation, training for highly qualified personnel and other programs and projects to benefit Canadians and leverage funding. Some examples include co-hosting scientific conferences and training workshops, producing white papers and recommendation guidelines, and public outreach initiatives.
  • CCRM, in partnership with University Health Network, has built a 20,000 ft2 (~1,900 m˛) state-of-the-art good manufacturing practices (GMP) facility that supports academic and private sector partners, and meets government regulatory requirements for manufacturing cells for clinical use.
  • CCRM has 10 companies in its portfolio. ExCellThera is a spin-off (established in partnership with the Institute for Research in Immunology and Cancer – Commercialization of Research) and eight others have been supported financially and/or through foundational science. The 10th company, Notch Therapeutics, is the first to go end-to-end through CCRM’s incubation program.
  • CCRM realized its first exit from an early-stage investment, achieving a key milestone in its mission to reach sustainability and re-invest the fruits of success back into the ecosystem. AVROBIO, a gene therapy company, has executed a successful initial public offering on the NASDAQ (2018).
  • CCRM has signed a letter of intent with McMaster Innovation Park to build a 120,000 ft2 (~11,150m2) contract development and manufacturing organization (CDMO) to produce the materials required for commercial-scale manufacturing of cell and gene therapies.
  • With funding from Cytiva (formerly GE Healthcare) and the Federal Economic Development Agency for Southern Ontario, CCRM built a centre for advanced manufacturing in Toronto (2016). The Centre for Advanced Therapeutic Cell Technologies is providing cell therapy companies with the expertise to optimize manufacturing processes to produce the significant numbers of cells required for clinical and commercial use.

Connect with CCRM

 

News
Videos
Watch Video
CCRM’s Corporate Video
September 29, 2017
Watch Video
CCRM Sits Down With... Molly Shoichet, University of Toronto
May 1, 2014
Watch Video
Cell Culture with Bioreactors
March 31, 2014
Watch Video
CCRM Sits down with... Michael D. West, CEO of BioTime
November 29, 2013
Watch Video
CCRM Sits Down with... Stephen Minger
November 4, 2013